CHE CHEMED CORP
Services-Home Health Care Services · NYSE · SEC CIK 19584 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY1.3%
TTM EPS YoY10.5%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR4.9%
Margins
Gross margin33.6%
Operating margin13.9%
Net margin10.6%
FCF margin11.1%
EBITDA margin16.3%
Returns
ROE29.1%
ROA16.9%
ROIC (approx.)27.4%
Asset turnover1.59x
Leverage & solvency
Liabilities / assets49.9%
Debt / equity0.27x
Current ratio1.11x
Interest coverage75.39x
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio-4.8%
Payout ratio11.9%
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.53B | $2.43B |
| Cost of revenue | $1.71B | $1.58B |
| Gross profit | $823.18M | $854.35M |
| SG&A expense | $417.19M | $424.36M |
| Operating income | $338.25M | $366.49M |
| Interest expense | $1.75M | $1.78M |
| Pretax income | $355.78M | $399.46M |
| Income tax | $90.54M | $97.47M |
| Net income | $265.24M | $302.00M |
| EBITDA | $403.09M | $429.54M |
| EPS (basic) | 18.42 | 20.10 |
| EPS (diluted) | 18.34 | 19.89 |
| Dividends declared per share | 2.20 | 1.80 |
| Weighted avg. shares (diluted) | 14.46M | 15.19M |
| Balance sheet | ||
| Cash & equivalents | $74.52M | $178.35M |
| Receivables | $182.57M | $171.16M |
| Inventory | $7.54M | $8.19M |
| Current assets | $302.62M | $394.75M |
| PP&E, net | $205.66M | $200.84M |
| Goodwill | $667.00M | $666.74M |
| Intangibles | $82.76M | $92.21M |
| Total assets | $1.54B | $1.67B |
| Current liabilities | $287.13M | $285.69M |
| Total liabilities | $558.78M | $549.58M |
| Shareholders' equity | $979.40M | $1.12B |
| Cash flow statement | ||
| Operating cash flow | $388.27M | $417.50M |
| Capital expenditure | $62.80M | $49.53M |
| Free cash flow | $325.48M | $367.97M |
| Investing cash flow | -$59.34M | -$143.91M |
| Financing cash flow | -$432.77M | -$359.19M |
| Depreciation & amortization | $64.84M | $63.05M |
| Stock-based compensation | $38.68M | $52.11M |
| Dividends paid | $31.70M | $27.09M |
| Share buybacks | $431.50M | $361.39M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.